UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022.

Brussels (Belgium), 23 May 2022 – UCB, a global pharmaceutical company, today announced detailed results from two Phase 3 studies which evaluated the efficacy and safety of bimekizumab versus placebo in the treatment of adults with active psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naïve (BE OPTIMAL) and in adults who had an inadequate response or intolerance to tumour necrosis factor inhibitors (BE COMPLETE). [i] , [ii] The safety and efficacy of bimekizumab in psoriatic arthritis have not been established, and it is not approved for use in psoriatic arthritis...